COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: They will receive 400 mg of hydroxychloroquine (Tehran Darou, Iran) a week for eight weeks and also this group will receive routine care for Corona's new disease. I
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: consent to participate in the study People working in medical centers in Arak city Lack of sensitivity to hydroxychloroquine Lack of G6PD Lack of porphyria No breastfeeding No pregnancy Lack of diabetes, kidney , liver and skin disease
Exclusion criteria
Exclusion criteria: Lack of desire to continue studying Having major side effects from medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of confirmed cases. Timepoint: At the beginning and 2 months after the start of the study. Method of measurement: Checklist.;Serum CRP levels and cellular immunity (cd8 / cd4 ratio) are assessed at the beginning and end of the study for all subjects. Timepoint: At the beginning and 2 months after the start of the study. Method of measurement: Checklist.;The two groups will also be examined in terms of disease severity (need for intubation, ICU hospitalization) and absolute lymphocyte count. Timepoint: At the beginning and 2 months after the start of the study. Method of measurement: Checklist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Ramin Parvizrad
Arak University of Medical Sciences
Outcome results
None listed